Amylyx Pharmaceuticals Inc - Asset Resilience Ratio
Amylyx Pharmaceuticals Inc (AMLX) has an Asset Resilience Ratio of 76.14% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See AMLX current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2025)
This chart shows how Amylyx Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Amylyx Pharmaceuticals Inc balance sheet assets.
Liquid Assets Composition Over Time
This chart breaks down Amylyx Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Amylyx Pharmaceuticals Inc (AMLX) financial obligations for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $201.43 Million | 76.14% |
| Total Liquid Assets | $201.43 Million | 76.14% |
Asset Resilience Insights
- Very High Liquidity: Amylyx Pharmaceuticals Inc maintains exceptional liquid asset reserves at 76.14% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Amylyx Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Amylyx Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 1.48% |
|
Zhejiang Huahai Pharmaceutical Co Ltd
SHG:600521 |
Drug Manufacturers - Specialty & Generic | 0.35% |
|
Beijing Tongrentang Co Ltd
SHG:600085 |
Drug Manufacturers - Specialty & Generic | 0.50% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS
IS:ECILC |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Heilongjiang ZBD Pharmaceutical Co Ltd
SHG:603567 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Teyi Pharmaceutical Group Co Ltd
SHE:002728 |
Drug Manufacturers - Specialty & Generic | 9.66% |
Annual Asset Resilience Ratio for Amylyx Pharmaceuticals Inc (2020–2025)
The table below shows the annual Asset Resilience Ratio data for Amylyx Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 27.15% | $90.33 Million | $332.64 Million | -24.03pp |
| 2024-12-31 | 51.18% | $99.11 Million | $193.63 Million | +12.31pp |
| 2023-12-31 | 38.88% | $201.16 Million | $517.45 Million | -33.78pp |
| 2022-12-31 | 72.66% | $284.42 Million | $391.45 Million | +29.17pp |
| 2021-12-31 | 43.49% | $45.93 Million | $105.61 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $14.10 Million | -- |
About Amylyx Pharmaceuticals Inc
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and… Read more